Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Why Opendoor Technologies Stock Popped Today (Fool) +++ OPENDOOR Aktie -3,33%

Gewinn & Umsatz News zur INCYTE Aktie

 >INCYTE Aktienkurs 
58.3 EUR    -1.0%    (Tradegate)
Ask: 59.78 EUR / 93 Stück
Bid: 59.2 EUR / 93 Stück
Tagesumsatz: 1 Stück
Realtime Kurs von 8 bis 22 Uhr!
INCYTE Aktie über LYNX handeln
>INCYTE Performance
1 Woche: +0,1%
1 Monat: -5,0%
3 Monate: +13,6%
6 Monate: -17,1%
1 Jahr: -0,2%
laufendes Jahr: -11,3%
>INCYTE Aktie
Name:  INCYTE DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45337C1027 / 896133
Symbol/ Ticker:  ICY (Frankfurt) / INCY (NASDAQ)
Kürzel:  FRA:ICY, ETR:ICY, ICY:GR, NASDAQ:INCY
Index:  S&P500
Webseite:  https://incyte.com/
Marktkapitalisierung:  11620 Mio. EUR
Umsatz:  3869.93 Mio. EUR
EBITDA:  266.14 Mio. EUR
Gewinn je Aktie:  0.158 EUR
Schulden:  37.84 Mio. EUR
Liquide Mittel:  2114.86 Mio. EUR
Umsatz-/ Gewinnwachstum:  19.5% / -6.7%
KGV/ KGV lG:  335.11 / 11.52
KUV/ KBV/ PEG:  3.09 / 3.54 / 0.12
Gewinnm./ Eigenkapitalr.:  0.48% / 0.47%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 1.371.411 USD.
Suchwörter:  INCYTE
Letzte Datenerhebung:  16.07.25
>INCYTE Eigentümer
Aktien: 193.57 Mio. St.
f.h. Aktien: 161.07 Mio. St.
Insider Eigner: 2.22%
Instit. Eigner: 100.6%
>INCYTE Peer Group

 
10.07.25 - 15:06
 Incyte′s Q2 2025 Earnings: What to Expect (Barchart)
 
Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge in profitability, projecting triple-digit year-over-year profit growth....
29.04.25 - 14:18
 Incyte Q1 Results Top Estimates (AFX)
 
WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) on Tuesday reported net income of $158.20 million or $0.80 per share for the first quarter, lower than $169.55 million or $0.75 per share in the prior-ye......
16.04.25 - 13:30
 Incyte Earnings Preview: What to Expect (Barchart)
 
Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth....
09.03.25 - 04:01
 Lilly Reveals Positive Phase 3 Results For Adolescent Alopecia Areata Treatment With Baricitinib (AFX)
 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) and Incyte's (INCY) late-breaking results from Phase 3 BRAVE-AA-PEDS study found adolescent patients (ages 12 to under 18) with severe alopecia are......
10.02.25 - 14:18
 Incyte Q4 Adj. EPS Misses Estimates, Revenues Beat; Sees Revenue Growth In FY25 (AFX)
 
WASHINGTON (dpa-AFX) - Pharma company Incyte Corp. (INCY) reported Monday slightly higher earnings in its fourth quarter with strong growth in revenues. Adjusted earnings missed the Wall Street vi......
17.01.25 - 09:30
 What You Need to Know Ahead of Incyte€s Earnings Release (Barchart)
 
Biopharma major Incyte is expected to announce its fourth-quarter results later this month and analysts expect a significant double-digit growth in earnings....
07.12.24 - 13:43
 Incyte Announces Positive Results From Phase 3 Trial Evaluating Retifanlimab (Zynyz®) (Reuters EN)
 
BRIEF-Incyte Announces Positive Results From Phase 3 Trial Evaluating Retifanlimab (Zynyz®) Dec 7 (Reuters) - INCYTE ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL EVALUATING RETIFANLIMAB (ZYNYZ®) IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER INCYTE CORP - ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL...
29.10.24 - 16:05
 Incyte climbs on 2024 sales forecast lift for top-selling drug Jakafi (Reuters EN)
 
Incyte climbs on 2024 sales forecast lift for top-selling drug Jakafi...
29.10.24 - 14:58
 Incyte raises 2024 sales forecast for top-selling drug Jakafi (Reuters EN)
 
Incyte raises 2024 sales forecast for top-selling drug Jakafi...
29.10.24 - 13:01
 Incyte Corporation Q3 Profit Drops, Inline With Estimates (AFX)
 
WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) released earnings for third quarter that decreased from last year in line with the Street estimates.The company's bottom line came in at $106.456 m......
29.10.24 - 12:26
 Incyte Reports 2024 Third Quarter Financial Results And Provides Updates On Key Clinical Programs (Reuters EN)
 
Incyte Reports 2024 Third Quarter Financial Results And Provides Updates On Key Clinical Programs...
19.09.24 - 03:24
 Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal (AFX)
 
WASHINGTON (dpa-AFX) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adu......
15.08.24 - 23:07
 Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®) (Reuters EN)
 
Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®)...
30.07.24 - 15:02
 Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi (Reuters EN)
 
Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi...
30.07.24 - 13:48
 Incyte Corporation Q2 Earnings Summary (AFX)
 
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Incyte Corporation (INCY):Earnings: -$444.601 million in Q2 vs. $203.548 million in the same period last year. EPS: -$2.04 in Q2 vs. $0......
26.07.24 - 14:32
 Incyte Corp <INCY.OQ> expected to post earnings of $1.11 a share - Earnings Preview (Reuters EN)
 
Incyte Corp <INCY.OQ> expected to post earnings of $1.11 a share - Earnings Preview...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Malern und Dichtern war es stets gleichermaßen erlaubt zu sagen, was auch immer ihnen beliebt. - Quintus Flaccus Horaz
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!